Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATP4A | P20648 | 3/20 | 0.54 |
| ▸ | ATP4B | P51164 | 3/20 | 0.54 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.48 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.43 |
| ▸ | DHODH | Q02127 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL203816 | 0.83 | CYP19A1 (0.56) | ATP4AATP4BCYP19A1NPC1RAB9A | |
| SCHEMBL12328084 | 0.83 | CYP19A1 (0.53) | ATP4AATP4BCYP19A1NPC1RAB9A | |
| SCHEMBL5094282 | 0.81 | ALDH1A1 (0.55) | ATP4AATP4BCYP19A1NPC1RAB9A | |
| SCHEMBL13017084 | 0.80 | CYP19A1 (0.49) | ATP4AATP4BCYP19A1NPC1RAB9A | |
| SCHEMBL12067391 | 0.77 | CYP19A1 (0.57) | ATP4AATP4BCYP19A1NPC1RAB9A | |
| SCHEMBL27751529 | 0.77 | ATP4A (0.58) | ATP4AATP4BCYP19A1NPC1RAB9A | |
| SCHEMBL14765480 | 0.77 | L3MBTL1 (0.53) | ATP4AATP4BCYP19A1NPC1RAB9A | |
| SCHEMBL18037161 | 0.76 | HTR3A (0.58) | ATP4AATP4BCYP19A1NPC1RAB9A | |
| SCHEMBL30123146 | 0.75 | HSD17B10 (0.62) | ATP4AATP4BCYP19A1NPC1RAB9A | |
| SCHEMBL1745076 | 0.75 | LOXL2 (0.64) | ATP4AATP4BNPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394841-B2 | Compounds and methods for modulating G protein-coupled receptors | IRM LLC (BM) | 2013-03-12 | — | — | US | disclosed |
| US-8394841-B2 | Compounds and methods for modulating G protein-coupled receptors | IRM LLC (BM) | 2013-03-12 | — | — | US | disclosed |
| US-8394841-B2 | Compounds and methods for modulating G protein-coupled receptors | IRM LLC (BM) | 2013-03-12 | — | — | US | disclosed |
| US-8088791-B2 | Antibacterial agents | Biots Scientific Management Pty Ltd (AU) | 2012-01-03 | — | — | US | disclosed |
| US-20100035944-A1 | COMPOUNDS AND METHODS FOR MODULATING G PROTEIN-COUPLED RECEPTORS | IRM LLC (BM) | 2010-02-11 | — | — | US | disclosed |
| US-20100035944-A1 | COMPOUNDS AND METHODS FOR MODULATING G PROTEIN-COUPLED RECEPTORS | IRM LLC (BM) | 2010-02-11 | — | — | US | disclosed |
| US-20100035944-A1 | COMPOUNDS AND METHODS FOR MODULATING G PROTEIN-COUPLED RECEPTORS | IRM LLC (BM) | 2010-02-11 | — | — | US | disclosed |
| EP-2125758-A1 | COMPOUNDS AND METHODS FOR MODULATING G PROTEIN-COUPLED RECEPTORS | IRM LLC (BM) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008103501-A1 | COMPOUNDS AND METHODS FOR MODULATING G PROTEIN-COUPLED RECEPTORS | IRM LLC (BM) | 2008-08-28 | — | — | WO | disclosed |
| WO-2008103501-A1 | COMPOUNDS AND METHODS FOR MODULATING G PROTEIN-COUPLED RECEPTORS | IRM LLC (BM) | 2008-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035944-A1 | COMPOUNDS AND METHODS FOR MODULATING G PROTEIN-COUPLED RECEPTORS | GRK2, GRK3, GRK5 | ATP4A 2974/4885ATP4B 3456/4885CYP19A1 2227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.